|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that proNGF is an important factor involving AD pathogenesis.
|
19680737 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Drug treatment strategies to enhance production of NGF in the CNS may be useful in the treatment of AD.
|
11230869 |
2001 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
According to much research, neurodegeneration and cognitive decline in Alzheimer disease (AD) are correlated with alternations of neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor.
|
29114922 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This change along with an increased TrkA/p75<sup>NTR</sup> ratio of nerve growth factor receptors in the hippocampus may contribute to increased density of immature neurons that we observed at the progressive stage of AD-like pathology in OXYS rats.
|
30415068 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF) deficiency has been suggested as a possible cause of the neural degeneration characteristic of Alzheimer's disease, and trypsin and gamma-NGF are the two enzymes that have been shown to be capable of processing beta-NGF precursor to active, mature beta-NGF in vitro, therefore, the specificity of purified recombinant ABPP Kunitz inhibitor was analyzed with respect to these two proteases.
|
1696210 |
1990 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor is a therapeutic candidate for Alzheimer's disease.
|
28031222 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we observed whether NGF can affect cholinergic neurons to change amyloid-β precursor protein (APP) metabolism process and reduce amyloidosis in AD brains.
|
24813062 |
2014 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neurotrophins, including nerve-growth factor and brain-derived neurotrophic factor, have been implicated in Alzheimer's disease (AD).
|
28498887 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The released NGF exhibits a substantial neuroprotective effect in differentiated rat pheochromocytoma PC12 cells against amyloid-beta (Aβ)-induced cytotoxicity, which is associated with Alzheimer's disease.
|
31482695 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The cross-talk between NGF and insulin pathways downstream the insulin receptor suggests novel potential therapeutic targets to slow cognitive decline in AD and diabetes-related brain insulin resistance.
|
29736736 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Correlation analysis confirms that neurotrophic factors (i.e., NGF, BDNF) play a great role in AD while are absent in LOBD pathophysiology.
|
28670271 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Initial efforts attempted to use NGF agonistically for Alzheimer's disease and neuropathies.
|
31026504 |
2020 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this article, we examine whether and how the progressive neurodegenerative phenotype of AD11 mice could be prevented or ameliorated by pharmacological treatments with NGF or the cholinergic agonist galantamine, at a relatively early phase of Alzheimer's disease-like neurodegeneration.
|
12205295 |
2002 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In a multicenter phase 2 trial, 49 participants with mild to moderate AD were randomly assigned in a 1:1 ratio to receive stereotactically guided intracerebral injections of AAV2-NGF or sham surgery.
|
29582053 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment of degenerating basal forebrain cholinergic neurons with nerve growth factor (NGF) in Alzheimer's disease has long been contemplated, but an effective and safe delivery method has been lacking.
|
18439998 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
But while NGF distinctly promoted neurite branching and elongation, Abeta was less effective in neurite elongation and counts of small processes and of growth cones remained clearly elevated after 24-h stimulation; these peculiarities might be linked to aberrant neuronal connections reported for an animal model of Alzheimer disease.
|
16001231 |
2005 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This chapter reviews the development of neurotrophic factor gene therapy for neurodegenerative diseases focusing on the therapeutic potential of nerve growth factor in Alzheimer's disease, currently the subject of a phase I clinical trial.
|
14699979 |
2004 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this article the authors summarize the development and implementation of nerve growth factor gene delivery as a potential means of reducing cell loss in AD.
|
15769074 |
2002 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In a previous study, AD patient's own fibroblasts genetically modified to produce NGF were transplanted directly into the brain and protected cholinergic neurons from degeneration and improved cognitive function in AD patients.
|
22526467 |
2012 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve Growth Factor (NGF) holds a great therapeutic promise for Alzheimer's disease, diabetic neuropathies, ophthalmic diseases, dermatological ulcers.
|
26371475 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve Growth Factor (NGF) is a therapeutic candidate for Alzheimer's disease, based on its well known actions on basal forebrain cholinergic neurons.
|
30391352 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Further, gradual dysregulation of neurotrophic factors like NGF and brain derived neurotrophic factor (BDNF) have been reported during AD development thus intensifying further research in targeting these factors as disease modifying therapies against AD.
|
30804738 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
A demonstration that neutralizing NGF activity could have consequences beyond a direct interference with the cholinergic system came from studies in the AD11 mouse model, in which the expression of a highly specific anti-NGF antibody determines a neurodegeneration that encompasses several features of human AD.
|
20566851 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
NGF deficiency in the basal forebrain precedes degeneration of basal forebrain cholinergic neurons in Alzheimer's disease, contributing to memory decline.
|
31301255 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease.
|
19606067 |
2009 |